https://www.selleckchem.com/pr....oducts/GSK1904529A.h
ter nerve injury are at least partly attributable to blocking propagation of this SA. Tapering opioids for chronic pain can be challenging for both patients and prescribers, both of whom may be unsure of what to expect in terms of pain, distress, activity interference, and withdrawal symptoms over the first few weeks and months of the taper. To better prepare clinicians to provide patient-centred tapering support, the current research used prospective longitudinal qualitative methods to capture individual-level variation in patients
Like
Comment
Share
